key: cord-0703167-nkqw9quv authors: Moreira, Renato Simões; Filho, Vilmar Benetti; Calomeno, Nathália Anderson; Wagner, Glauber; Miletti, Luiz Claudio title: EpiBuilder: A Tool for Assembling, Searching, and Classifying B-Cell Epitopes date: 2022-05-11 journal: Bioinform Biol Insights DOI: 10.1177/11779322221095221 sha: 7dcfda606355e01ed14035e9b4cca2565e427ed7 doc_id: 703167 cord_uid: nkqw9quv Epitopes are portions of a protein that are recognized by antibodies. These small amino acid sequences represent a significant breakthrough in a branch of bioinformatics called immunoinformatics. Various software are available for linear B-cell epitope (BCE) prediction such as ABCPred, SVMTrip, EpiDope, and EpitopeVec; a well-known BCE predictor is BepiPred-2.0. However, despite the prediction, there are several essential steps, such as epitope assembly, evaluation, and searching for epitopes in other proteomes. Here, we present EpiBuilder (https://epibuilder.sourceforge.io), a user friendly software that assists in epitope assembly, classifying and searching using input results of BepiPred-2.0. EpiBuilder generates several output results from these data and supports a proteome-wide processing approach. In addition, this software provides the following features: Chou & Fasman beta-turn prediction, Emini surface accessibility prediction, Karplus and Schulz flexibility prediction, Kolaskar and Tongaonkar antigenicity, Parker hydrophilicity prediction, N-glycosylation domains, and hydropathy. These information generate a unique topology for each epitope, visually demonstrating its characteristics. The software can search the entire epitope sequence in various FASTA files, and it allows to use BLASTP to identify epitopes that eventually have sequence variations. As an EpiBuilder application, we developed a epitope dataset from the protozoan Trypanosoma brucei gambiense, the gram-positive bacterium Clostridioides difficile, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Immune responses are divided into innate and adaptive responses. The adaptive immune response appears as a response to a large number of substances and adapts to them. It is characterized by specificity (ability to distinguish different substances) and memory (ability to respond more vigorously to repeated infection). The components of adaptive immunity are lymphocytes and their secretions, including antibodies or immunoglobulins (secreted by B lymphocytes or B cells). 1 Secreted antibodies recognize a specific part of the antigen, called an epitope, 2 bind together, neutralize it (preventing it from infecting cells), or mark it for elimination through, for example, phagocytosis, activation of the classical complement pathway, and recognition by eosinophils of immunoglobulin E bound to the pathogen followed by the release of granules harmful to the invading microorganism. Antibodies are the only components of adaptive immunity that prevent infections. Therefore, the production of potent antibodies is the objective of vaccination. 1 The identification of B-cell epitopes (BCEs) is of great importance for the development of vaccines, immunodiagnostics, and therapeutic antibodies. 2 In this regard, we present EpiBuilder, a tool capable of assembling BCEs from data generated by BepiPred-2.0, and from these data, the tool assists the researcher in several types of experiments, including those on a proteome-wide scale. EpiBuilder was developed using the Java programming language (supported by version 1.8) with a graphical user interface (GUI) and command-line options, without any additional prerequisite to perform all functions except BLASTP if this is set. EpiBuilder is prepared to run on any operating system that supports Java technology, such as Windows, MacOS, and Unix-based systems. In addition to the aforementioned versions, we developed an EpiBuilder version with a GUI for the Galaxy platform. 20 The interfaces were developed and validated using the Planemo (https://planemo.readthedocs.io) program, following the recommendations of good galaxy tool development practices. Galaxy is an open-source framework that aims to facilitate the reproducibility of bioinformatic analyses and access tools for various types of analysis. 20 The platform allows the user to adapt any program that runs along the command line to a graphical interface. Open servers (https://usegalaxy.org) make analytics more accessible when dealing with large volumes of data, and tools and interfaces are shared with the entire community through the Galaxy ToolShed repository. 21 The repository extends the Galaxy service for developers to create and publish new tools or adaptations of the existing programs. The GUI and terminal mode executable files, in addition to the source code, are available at https://epibuilder.sourceforge. io. The EpiBuilder galaxy version is available in ToolShed under the name EpiBuilder. There are 3 primary forms of system inputs: the first is the CSV file (comma separated values) generated by BepiPred-2.0 22 and the second is the result generated by BepiPred-2.0 through the output of the B-Cell Standalone IEDB program (http:// tools.iedb.org/bcell/). 23 The third option allows the user to input a job id (the number used to run BepiPred-2.0 online), and after the process is finished, the file can be downloaded from the BepiPred-2.0 server. The file generated by BepiPred-2.0 22 is uploaded to EpiBuilder, the proteins are reassembled from these data, and the scores are calculated for the following features: Emini surface accessibility, 16 Parker hydrophilicity, 19 Chou & Fasman beta-turn, 15 Karplus & Schulz flexibility, 17 and Kolaskar and Tongaonkar. 18 These scores are calculated internally by EpiBuilder, and such calculations have been rewritten in Java based on the IEDB B-Cell Standalone Python script. In addition, the molecular mass (MW), isoelectric point (pI), and hydropathy index of each amino acid are calculated using the BioJava library. 24 The epitopes are mounted from the threshold of BepiPred-2.0 (default value of 0.6). That is, if the amino acid score is greater than or equal to the cutoff point, it will be concatenated with the following amino acid with a score greater than or equal to the cutoff point. When an amino acid with a score less than the cutoff point is identified, the process reserves the generated epitope. Then, these epitopes are filtered so that only those between the minimum (default value 10) and maximum (default value 30) remain. Next, the presence of the N-glycosylation site is verified by searching for the Asn-Xaa-(Ser/Thr) domain, where Xaa is any amino acid except Proline. 25 Topology For each identified epitope, an individual analysis of amino acids is performed for the features chosen by the user. If the amino acid has a score equal to or above the threshold chosen for the feature, and the threshold can be calculated (default) or informed by the user, the current amino acid in question receives a representative character "E" when the assigned value is lower. Finally, a structure called All Matches is generated, which includes the amino acids with a score above or equal to the cutoff point for all selected functionalities; thus, it is possible to evaluate the specific stretches in which there is consensus in the analyzed structures. All Matches also receive a coverage value relative to the epitope. Along with these excerpts of the topology, the N-glycosylation sites are also informed through the character "E". If the amino acid has a hydropathy index less than 0, it is assigned the character "-", and if it is greater than or equal to 0, it is assigned the character. The case of epitope topology PSSHPAPQQQQAYYQ extracted from the tbg972.9.8930 protein of Trypanosoma brucei gambiense reference proteome (strain TREU927, TriTrypdb version 49) is shown in Figure 1 . For each feature, the number of amino acids above the cutoff point is determined, thus generating the percentage coverage of each feature in relation to the complete epitope. The average of all coverage values is calculated by generating the Avg cover attribute and these values appear in the descending order during the generation of data. The epitopes generated are identified in the proteomes informed (FASTA file) by the user. The proteomes are loaded into the RAM, and the search is performed by searching for the complete epitope sequence in the proteins. Therefore, we recommend adjusting the execution memory of the java parameters settings, -Xms (start memory) and -Xmx (max memory), according to the file size of the proteomes. 3 The search can also be performed by BLASTP 26 (requires prior installation on the computer), which is necessary to inform the location of the installation in the execution command or in the graphical interface (if the command is already in the system $PATH, one can inform only the blastp and makeblastdb commands, without full path). The identity (default value 90), cover (default value 90), word size (default value 4), and task (blastp-short default value) parameters can also be adjusted. The Blastp results are converted internally and integrated with the EpiBuilder result, and next to the positive hit, the protein accession number is added to the identity and coverage if the user wants to know the hits. For extensive searches, it is suggested that this configuration be removed. As these are small sequences for searching, it is important to evaluate blastp values, as they can eliminate results by exchanging only 1 amino acid. For EpiBuilder installed via Galaxy ToolShed, if a BLASTP search is chosen, the blastp and makeblastdb commands are required to be on the system $PATH. For the desktop version, there is a test option to verify that the blastp and makeblastdb commands setup is correct. The output files are generated with the name epibuilder-., so the user can perform multiple experiments in the same directory by swapping the of the experiment in question. The files generated are listed in Table 1 . If the user chooses to run the query via BLASTP, all output files generated by BLASTP follow the -epibuilder-blast-., and the result of BLASTP is generated in the CSV standard. The full EpiBuilder Stream is shown in Figure 2 . For the experiments, we selected 3 human pathogens: the protozoan T. b. gambiense, causative agent of human African trypanosomiasis (HAT-sleeping sickness), a fatal neglected tropical disease 27, 28 ; the gram-positive bacterium Clostridioides difficile, formerly called Clostridium difficile, which causes severe diarrhea, colitis, toxic megacolon, and potentially death 29, 30 ; and SARS-CoV-2, also fatal 31 which caused a pandemic in 2020. 32 The proteomes of SARS-CoV-2 (UP000464024, Uniprot), Clostridioides difficile (NCBI: txid1496), and T. b. gambiense (strain DAL972, TriTrypdb version 49) were downloaded and manually preprocessed to eliminate characters other than valid amino acids such as "*" and "X", which is a condition for running BepiPred-2.0. The proteomes were submitted to BepiPred-2.0 analysis using the B-Cell Standalone IEDB software, and this result was used as an input for EpiBuilder with the following configurations: BepiPred-2.0 threshold (0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, and 0.9), minimum epitope size (10) , and maximum epitope size (30) , all parameters were selected with default cutoff points. The searches were performed with the direct search of the sequence, as well as with the BLASTP option with identity parameters = 90, coverage = 90, word size = 4, and search method = blastp-short. In all experiments, the proteome was included in the search for epitopes that were repeated in other proteins. In addition, for each experiment, epitopes were searched in the human proteome (UP000005640, Uniprot). To search for T. b. gambiense, we used the proteomes of Trypanosoma brucei brucei (strain TREU927, TriTrypdb version 49), Trypanosoma evansi (strain STIB902, TriTrypdb version 49), Trypanosoma congolense (strain IL3000, TriTrypdb version 49), and Trypanosoma vivax (strain Y486, TriTrypdb version 49). For C. difficile, we used the proteomes of Clostridium For runs with SARS-CoV-2 in addition to the proteome and human proteome, we also added a database of spike proteins (4 854 709 proteins) and all deposited proteins (133 081 009 proteins) in GISAID to the day (November 9, 2021). Blastp evaluation in this round was suppressed because of the number of sequences. The last experiment with SARS-CoV-2 used the assembly of epitopes from the proteins S (spike), M (membrane), N (nucleocapsid), and E (envelope) of the Reference of SARS-CoV-2 (UP000464024, Uniprot) and were submitted to EpiBuilder to search for the respective proteins of the VoC (variant of concern) lines obtained from GISAID: alpha (EPI_ISL_6949888), beta (EPI_ISL_5905874), gamma (EPI_ISL_6943989), delta (EPI_ ISL_6950127), and omicron (EPI_ISL_6914032). The genomes obtained from GISAID were submitted to NextStrain 33 for assembly, protein prediction, and lineage confirmation (Supplementary Figure 1) . For this experiment, the BepiPred-2.0 threshold = 0.6 was explicitly chosen. Finally, the SARS-CoV-2 proteins sequences of the reference, alpha, beta, gamma, delta, and omicron were aligned with Clustal Omega 34 (https://www.ebi.ac.uk/Tools/msa/clustalo/) with the default parameters values to verify mutations in the epitopes, and the results were organized by Jalview 35 omitting the regions that were not predicted as epitopes. In all experiments, epitopes were found up to a threshold of 0.75; from threshold = 0.8, no epitopes were identified in any of the experiments ( Table 2 ). Table 3 shows that the epitope with the most occurrences of spike protein was CTEVPVAIHADQ, which was present in ~99% of the proteins of the protein spikes bank and ~4% of the complete protein bank (133 081 009). The other epitopes MSLGAENSVAY and YRLFRKSNLKP were found in ~95% and NNLDSKVGGN and DEVRQIAPGQTGK in ~95%, which shows their exemplary conservation. No epitope contained N-glycosylation sites. Full results can be seen in Supplementary Data 1. Considering the S, N, M, and E proteins of SARS-CoV-2, only protein E had no epitopes predicted for the adjusted values. Protein S presented 6 epitopes, some of which were completely identified in VoC sequences only by BLASTP, indicating amino acid exchanges in the epitopes of these variants, which is the case for the epitope QTQTNSPRRARSVA, whose sequence with the search for the complete structure only had an occurrence in the beta and gamma variants. Even with the blastp search, there was no occurrence of these epitopes in the omicron variant, including the epitope NNLDSKVGGN. The complete list of epitopes with their hits is shown in Table 4 , and the alignment with the epitopes of the S protein can be seen in Figure 5 , which precisely shows the exchange of a single Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. SCoV indicates SARS-CoV-2. It was identified a total of 29 epitopes. The search was performed using the GISAID database protein for spike and all proteins. amino acid in the alpha, delta, and omicron variants in the epitope QTQTNSPRRARSVA and the exchange of 2 amino acids in the epitope NNLDSKVGGN only in the omicron variant. Other data are presented in Supplementary Data 2. There were no occurrences of epitopes of SARS-CoV-2 in the human proteome according to the established criteria. However, by individually analyzing the files generated by BLASTP, it can be seen that if the values of identity and coverage were 50%, there would be several valid hits, such as the epitope QTQTNSPRRARSVA with 100% coverage hit and 50% identity in the genes |Q92902| HPS1_HUMAN (SPRRARS), |J3KPV6| J3KPV6_HUMAN (RRARSVA), sp|P37088| SCNNA_HUMAN (RRARSVA), and |C5HTZ1| C5HTZ1_HUMAN (RRARSVA). The epitope DEVRQIAPGQTGK had 17 hits, the epitope MSLGAE NSVAY had 2 hits, and the epitope CTEVPVAIHADQ had only 1 hit. Considering the threshold point of 0.75, 7 epitopes of C. difficile were identified (Table 5) , 5 of which presented N-glycosylation sites. Epitopes were not found in the other Clostridioides species either directly or by BLASTP. However, similar to SARS-CoV-2, if the identity and coverage values were modified to 60% coverage and identity, it was possible to find several hits. The exciting thing is that despite this, 54 hits were found with BLASTP, including 2 directly from the 9 epitope ASSSSSSSSN in humans. In addition, the epitopes identified showed almost 100% coverage in the selected features, except for the Kolaskar 18 method, increasing the value of EpiBuilder's Avg cover. Additional information is available in Supplementary Data 3. Considering the threshold of 0.75, we found 8 epitopes, 3 of them had N-glycosylated sites ( Table 6 ). The presence of epitopes with a small variety of amino acids was noted, with the most frequent epitopes being asparagine (N) and glutamine (Q). The higher frequency of occurrence of epitopes in T. evansi than that in T. b. brucei was also verified. In T. congolense and T. vivax, epitopes were not identified via direct search, but for T. vivax, the occurrence of the epitope QQQQQQQQQQQQQQLl was observed 27 times via BLASTP, and this same epitope had the occurrence of 416 in humans. Additional information is available in Supplementary Data 4. EpiBuilder is designed to be an intuitive and easy-to-use tool, with no installation required, and it can be rotated via the terminal, on servers for heavier processing, or on a personal computer with a GUI. This tool is also available for the Galaxy platform through ToolShed and can be installed on any server. Because it is an assembly tool based on the results of BepiPred-2.0, we understand that there is no comparative software because this tool is a pipeline tool to generate several results that would be done manually. After execution, we verified the possibility of running EpiBuilder as a proteome-wide tool for epitope generation, searching, and classification. From the executions, we noticed TBG TBB TCO TEV TVI HSAP TBG TBB TCO TEV TVI Xno hit identified for the epitope, when the value is 0, that is, there was hit but did not reach the cutoff point of coverage and identity. that finding epitopes with a threshold of BepiPred-2.0 greater than or equal to 0.8 was challenging; there were no results for all 3 evaluated organisms. An experiment with SARS-CoV-2 did not generate any identifiable epitopes in humans. However, this result can change according to the settings. We also noticed that for T. b. gambiense and C. difficile, some of the epitopes generated did not occur in humans in general, even with BLASTP consultation, which may indicate potential targets with less possibility of cross-reaction. We found that the higher the threshold of the established BepiPred-2.0, the greater the coverage of the selected EpiBuilder features, which shows a direct relationship between these features and the threshold definition. As these are genome-wide experiments, these results need to be validated more cautiously because they may contain data from the assembly and prediction of proteins generated with some type of error. The next steps of EpiBuilder are will be to allow the use of results from other BCE predictors and integrate them using docker to turn the application more accessible for the non-specialist. Cellular and Molecular Immunology Antibody informatics for drug discovery iBCE-EL: a new ensemble learning framework for improved linear B-cell epitope prediction Designing a novel mRNA vaccine against SARS-CoV-2: an immunoinformatics approach Bioinformatics analysis of SARS-CoV-2 to approach an effective vaccine candidate against COVID-19 Bioinformatics analysis of ROP8 protein to improve vaccine design against Toxoplasma gondii Genome-wide analysis of excretory/secretory proteins in Trypanosoma brucei brucei: insights into functional characteristics and identification of potential targets by immunoinformatics approach A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice Exploring Leptospiral proteomes to identify potential candidates for vaccine design against Leptospirosis using an immunoinformatics approach Cancer immunoinformatics: a promising era in the development of peptide vaccines for human papillomavirus-induced cervical cancer Prediction of continuous B-cell epitopes in an antigen using recurrent neural network SVMTriP: a method to predict B-cell linear antigenic epitopes EpiDope: a deep neural network for linear B-cell epitope prediction EpitopeVec: linear epitope prediction using deep protein sequence embeddings Prediction of the secondary structure of proteins from their amino acid sequence Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide Prediction of chain flexibility in proteins -a tool for the selection of peptide antigens A semi-empirical method for prediction of antigenic determinants on protein antigens New hydrophilicity scale derived from highperformance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update Dissemination of scientific software with Galaxy ToolShed BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes The Immune Epitope Database (IEDB): 2018 update BioJava 5: a community driven open-source bioinformatics library N-GlyDE: a twostage N-linked glycosylation site prediction incorporating gapped dipeptides and pattern-based encoding Gapped BLAST and PSI-BLAST: a new generation of protein database search programs Human African trypanosomiasis Update on human African trypanosomiasis (sleeping sickness) Clostridium difficile infection: review Clostridium difficile infection and antibiotic-associated diarrhoea SARS-CoV-2: structure, biology, and structure-based therapeutics development SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in Wuhan populations Nextstrain: real-time tracking of pathogen evolution Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega Alignment of biological sequences with Jalview All the experimental data, source code, and binaries are available in https://epibuilder.sourceforge.io. Supplemental material for this article is available online.